Acromegaly

New Instrument Measuring Treatment Satisfaction May Benefit Patients With Acromegaly

New Instrument Measuring Treatment Satisfaction May Benefit Patients With Acromegaly

By

A new instrument may provide physicians insight into satisfaction with acromegaly treatment.

Acromegaly Diagnosis Delayed in Elderly Woman

Acromegaly Diagnosis Delayed in Elderly Woman

The presence of a pituitary tumor on magnetic resonance imaging confirmed the diagnostic hypothesis.

Signifor Earns FDA Approval for Acromegaly

Signifor Earns FDA Approval for Acromegaly

By

The FDA has approved pasireotide (Signifor long-acting release) for treatment of acromegaly.

Genetic Cause of Gigantism Explored

Genetic Cause of Gigantism Explored

By

Researchers have discovered a single gene in a region of the X chromosome that may cause excessive growth in children.

Endocrine Society Releases Guidelines for Acromegaly

Endocrine Society Releases Guidelines for Acromegaly

By

The Endocrine Society has issued a clinical practice guideline for the diagnosis and treatment of acromegaly.

ATL1103 Decreases IGF-1 in Acromegaly Trial

ATL1103 Decreases IGF-1 in Acromegaly Trial

In patients with acromegaly, ATL1103 significantly reduced serum insulin-like growth factor I (IGF-1) after 14 weeks of treatment.

Thyroid Cancer, Nodular Disease Risk Increased in Acromegaly

Thyroid Cancer, Nodular Disease Risk Increased in Acromegaly

Thyroid nodular disease and thyroid cancer prevalence appears to be higher in patients with acromegaly.

Mixed Metabolic Profiles Found in Acromegaly Remission

By

Some cardiovascular risk factors and adiposity increased during acromegaly remission.

Long-Acting Release Signifor Effective in Acromegaly Trial

Long-Acting Release Signifor Effective in Acromegaly Trial

Novartis announced results from a phase 3 trial for Signifor LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

Sign Up for Free e-Newsletters

CME Focus